AstraZeneca: Carcinoma, Non-Small-Cell Lung trials

The registry lists 209 Carcinoma, Non-Small-Cell Lung studies with AstraZeneca as lead sponsor. 25 are open to participants now and 63 have results posted.

Phase 1 46Phase 2 48Phase 3 44Phase 4 10No phase 71(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC PatientsNot yet recruitingNCT07914972
• A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLCNot yet recruitingNCT07760519
• A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)RecruitingNCT07613424Not applicable
• Barriers and Facilitators of Persistence With Adjuvant OsimertinibRecruitingNCT07542210
• CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLCRecruitingNCT07413757
• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabRecruitingNCT07391670Phase 1
• A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in ChinaRecruitingNCT07316062
• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsRecruitingNCT07291037Phase 3
• Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.RecruitingNCT07279935Phase 4
• A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsRecruitingNCT07115043Phase 1/2
• A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07098338Phase 2
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06996782Phase 1/2
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerRecruitingNCT06868277Phase 3
• Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical RecordsNot yet recruitingNCT06842056
• UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ AllianceRecruitingNCT06726720
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)RecruitingNCT06692738Phase 3
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCRecruitingNCT06627647Phase 3
• NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic AlterationsRecruitingNCT06494540
• RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in BrazilRecruitingNCT06491862
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsRecruitingNCT06357533Phase 3
• Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT06350097Phase 3
• OSIREAL - Osimertinib RWE on EGFRm NSCLC in SpainRecruitingNCT06068049
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationRecruitingNCT05877599Phase 1
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingNCT05061550Phase 2
• Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCRecruitingNCT04686305Phase 1
• A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)Active, not recruitingNCT05460273Phase 1/2Results posted
• A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid TumoursTerminatedNCT05397171Phase 1/2Results posted
• A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCActive, not recruitingNCT05246514Phase 2Results posted
• Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).CompletedNCT05219162Phase 4Results posted
• A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04765059Phase 3Results posted
• Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.CompletedNCT04642469Phase 3Results posted
• A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive, not recruitingNCT04606771Phase 2Results posted
• Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLCCompletedNCT04416633Phase 4Results posted
• Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)CompletedNCT04385368Phase 3Results posted
• Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.TerminatedNCT04381494Phase 4Results posted
• A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerActive, not recruitingNCT04351555Phase 3Results posted
• Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for ChemotherapyCompletedNCT04249362Phase 2Results posted
• Durvalumab Long-Term Safety and Efficacy StudyCompletedNCT04078152Phase 4Results posted
• A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Active, not recruitingNCT04035486Phase 3Results posted
• Osimertinib Study in Indian PatientsCompletedNCT03853551Phase 4Results posted
• Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCCompletedNCT03822351Phase 2Results posted
• Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerCompletedNCT03794544Phase 2Results posted
• Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibActive, not recruitingNCT03778229Phase 2Results posted
• Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)Active, not recruitingNCT03775486Phase 2Results posted
• A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsActive, not recruitingNCT03706690Phase 3Results posted
• A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung CancerCompletedNCT03693300Phase 2Results posted
• A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)Active, not recruitingNCT03521154Phase 3Results posted
• Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung CancerCompletedNCT03519971Phase 3Results posted
• Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain MetastasesCompletedNCT03463525Phase 1Results posted
• Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination StudyActive, not recruitingNCT03381274Phase 1/2Results posted
• Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingNCT03334617Phase 2Results posted
• A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With OsimertinibCompletedNCT03239340Phase 2Results posted
• Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).Active, not recruitingNCT03164616Phase 3Results posted
• Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)Active, not recruitingNCT03003962Phase 3Results posted
• Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)Active, not recruitingNCT02542293Phase 3Results posted
• AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.Active, not recruitingNCT02511106Phase 3Results posted
• Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)Active, not recruitingNCT02453282Phase 3Results posted
• Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT02448303Phase 2Results posted
• Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia PacificCompletedNCT02442349Phase 2Results posted
• AZD2014 and Weekly Paclitaxel in Squamous NSCLCTerminatedNCT02403895Phase 2Results posted
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02352948Phase 3Results posted
• Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung CancerCompletedNCT02317016Phase 1Results posted
• AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT02296125Phase 3Results posted
• Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy VolunteersCompletedNCT02224053Phase 1Results posted
• Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLCCompletedNCT02197247Phase 1Results posted
• Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLCCompletedNCT02197234Phase 1Results posted
• Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT02179671Phase 2Results posted
• Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung CancerCompletedNCT02163733Phase 1Results posted
• Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)CompletedNCT02157883Phase 1Results posted
• A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerCompletedNCT02125461Phase 3Results posted
• Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive TumoursCompletedNCT02094261Phase 2Results posted
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02087423Phase 2Results posted
• A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung CancerTerminatedNCT02087176Phase 2Results posted
• Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCActive, not recruitingNCT01933932Phase 3Results posted
• Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung CancerCompletedNCT01809210Phase 1Results posted
• AZD9291 First Time In Patients Ascending Dose StudyCompletedNCT01802632Phase 1/2Results posted
• Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.CompletedNCT01750281Phase 2Results posted
• Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung CancerCompletedNCT01605916Phase 1Results posted
• A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy AloneCompletedNCT01544179Phase 3Results posted
• A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung CancerTerminatedNCT01268059Phase 1/2Results posted
• AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC PatientsCompletedNCT00890825Phase 2Results posted
• Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)CompletedNCT00770588Phase 4Results posted
• ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer StudyCompletedNCT00745875Phase 2Results posted
• SELINE: Second-Line Iressa Phase IV Study in NSCLC PatientsCompletedNCT00608868Phase 4Results posted
• Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT00536107Phase 4Results posted
• First Line IRESSA™ Versus Carboplatin/Paclitaxel in AsiaCompletedNCT00322452Phase 3Results posted
• Phase II Iressa & Carbo/Gem in NSCLCCompletedNCT00264498Phase 2Results posted
• The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck CancerCompletedNCT00243347Phase 1Results posted
• Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and OutcomesCompletedNCT07215026
• Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.CompletedNCT07213076
• A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active, not recruitingNCT06606847Phase 2
• A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D MutationTerminatedNCT06599502Phase 1
• A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesActive, not recruitingNCT06564844Phase 3
• Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) StudyActive, not recruitingNCT06494241
• Volrustomig Priming Regimens Exploratory Phase II Platform StudyActive, not recruitingNCT06448754Phase 2
• A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06417814Phase 3
• Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCActive, not recruitingNCT06376084
• Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic AlterationsActive, not recruitingNCT06245837
• Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsActive, not recruitingNCT06218914Phase 1
• Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILDTerminatedNCT06192004